- βCGM users gained over half a quality-adjusted life year compared to finger-stick users
- βCGM led to fewer long-term diabetes complications despite higher upfront device costs
- βCGM was well within accepted cost-effectiveness thresholds, supporting wider use
| Journal | Diabetes therapy : research, treatment and education of diabetes and related disorders |
| Year | 2025 |
| Authors | Jendle, Ilham, Alshannaq |
| PMID | 41175314 |
What Was Studied β and Why It Matters
For people with Type 2 diabetes who use insulin, checking blood sugar is a daily necessity. But there are two main ways to do it: traditional finger-stick testing (called self-monitoring of blood glucose, or SMBG) and continuous glucose monitors (CGM), small wearable sensors that track blood sugar automatically throughout the day and night.
Researchers in Sweden wanted to know: is switching from finger sticks to a real-time CGM actually worth the extra cost? They used a well-established diabetes modeling tool to compare long-term health outcomes and costs for both approaches β and their findings offer encouraging news for people managing insulin-treated Type 2 diabetes.
What the Researchers Found
The study used clinical data from a 12-month randomized controlled trial and ran projections over a patient's remaining lifetime. Here's what stood out:
- Longer life: People using CGM gained an average of about one additional month of life compared to those using finger sticks.
- Better quality of life: CGM users gained 0.63 additional quality-adjusted life years (QALYs) β a measure that accounts for both length and wellbeing β a meaningful improvement.
- Fewer complication costs: Although CGM devices cost more upfront, they led to fewer diabetes-related complications over time, which reduced long-term medical expenses.
- Cost-effective overall: The cost per quality-adjusted life year gained with CGM came out to roughly 219,000 Swedish Krona β well below Sweden's accepted value threshold of 500,000 SEK. In health economics, falling below that threshold means a treatment is considered worth the investment.
What This Means for Real Patients
If you're managing Type 2 diabetes with insulin, this research suggests that upgrading from finger-stick testing to a continuous glucose monitor isn't just more convenient β it's likely to improve your health outcomes and may save the healthcare system money in the long run by helping prevent serious complications like kidney disease, nerve damage, and heart problems.
CGMs provide real-time readings every few minutes, allowing you and your care team to spot dangerous highs and lows faster and make smarter adjustments to your insulin doses. That tighter control is what drives better outcomes.
For patients managing supplies and devices, MDS Diabetes offers a range of CGM-compatible products and diabetes management supplies to support a smooth transition to continuous monitoring.
Important Context
This study was conducted using Swedish healthcare costs, so exact dollar figures won't translate directly to other countries. However, similar cost-effectiveness findings have been seen in other health systems, making the core conclusion broadly relevant.
Bottom Line
For people with Type 2 diabetes who take insulin, continuous glucose monitors deliver measurably better health outcomes than traditional finger-stick testing β and are considered a cost-effective choice when viewed over a lifetime. If you're still relying solely on finger sticks, talk to your doctor about whether a CGM might be right for you.